NK cells can be transplanted across human leucocyte antigen (HLA)-boundaries and because of their shorter life span and their inability to produce interleukin-2 (IL-2), massive off-target side effects (i.e., brain edema) can be limited when compared to tumor-specific T cells as well as CAR-engineered T cells [12]. This evidence concerns the gene IL2 and neoplasm.